301075.SZ Stock Analysis
30
Uncovered
Tibet Duo Rui Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in research and development, manufacture, and sale of chemical preparations and their raw materials. The company is headquartered in Wuhan, Hubei and currently employs 299 full-time employees. The company went IPO on 2021-09-29. The firm's core product is sodium acetate ringer injection, which is mainly used to supplement body fluid, regulate electrolyte balance and correct acidosis. The firm's products also include its own products, compound electrolyte injection, compound mannitol injection and cefotaxime sodium for injection.